ProShares - Ultra Nasdaq Biotechnology (BIB) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.40: the stock has moved about 40% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerProShares - Ultra Nasdaq Biotechnology (BIB) trades at $112.08. ProShares Ultra Nasdaq Biotechnology (BIB) is a leveraged exchange-traded fund (ETF) that seeks to deliver twice the daily performance of the Nasdaq Biotechnology Index. Sector: Financials.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for BIB: BIB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
ProShares - Ultra Nasdaq Biotechnology (BIB) Financial Services Profile
ProShares Ultra Nasdaq Biotechnology (BIB) is a leveraged ETF aiming for 2x daily returns of the Nasdaq Biotechnology Index, offering amplified exposure to the biotech sector. With a $0.07 billion market cap and a beta of 1.40, it caters to investors seeking aggressive, short-term gains in biotechnology, while acknowledging the inherently higher risk.
What Is the Investment Thesis for BIB?
ProShares Ultra Nasdaq Biotechnology (BIB) presents a high-risk, high-reward investment proposition for sophisticated traders. Its core value driver is the 2x leveraged exposure to the Nasdaq Biotechnology Index, offering the potential for amplified gains in a bullish biotech market. A key catalyst is positive sentiment and momentum in the biotechnology sector, driven by factors like FDA approvals, breakthrough research, and M&A activity. Conversely, negative news or market corrections in the biotech space can lead to significant losses due to the fund's leveraged structure. The fund's daily rebalancing mechanism can also lead to erosion of value over time, especially in volatile or sideways-trending markets. Investors should carefully consider their risk tolerance and investment horizon before investing in BIB, recognizing that it is designed for short-term tactical trading rather than long-term portfolio diversification.
Based on FMP financials and quantitative analysis
BIB Key Highlights
BIB seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index.
- The fund has a market capitalization of $0.07 billion, indicating its relative size within the ETF market.
- BIB's beta of 1.40 suggests it is more volatile than the overall market, which is typical for leveraged ETFs.
- The fund does not offer a dividend yield, as its primary objective is to provide leveraged exposure to the biotechnology sector rather than generate income.
Who Are BIB's Competitors?
BIB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BKSE BNY Mellon US Small Cap Core Equity ETF | $42.35 | +0.62% | $83.9M | — |
| CAMX Cambiar Aggressive Value ETF | $33.07 | -0.74% | $62.2M | — |
| DIVL Madison Dividend Value ETF | $24.48 | +0.37% | $58.2M | — |
| GOP Unusual Whales Subversive Republican Trading ETF | $45.49 | +0.29% | $92.3M | — |
| ITDC iShares LifePath Target Date 2035 ETF | $36.72 | +0.55% | $103M | — |
| BLK BlackRock, Inc. | $1066.45 | +0.64% | $165B | 51 5-pillar |
| BX Blackstone Inc. | $111.64 | -0.09% | $136B | 68 5-pillar |
| APOS Apollo Global Management, Inc. | $25.59 | 0.00% | $74.8B | 56 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIB's Key Strengths?
Leveraged exposure to the biotechnology sector
- Flexibility to trade like a stock on exchanges
- Potential for amplified returns in a bullish market
- Part of the well-known ProShares ETF family
What Are BIB's Weaknesses?
High risk due to leveraged nature
- Daily rebalancing can lead to erosion of value over time
- Not suitable for long-term investment strategies
- Performance is heavily dependent on the movements of the Nasdaq Biotechnology Index
What Are the Key Risks for BIB?
Negative clinical trial results for major biotechnology companies within the Nasdaq Biotechnology Index.
- Regulatory setbacks or delays in the approval of new drugs and therapies.
- Increased competition from biosimilars and generic drugs.
- Market corrections or economic downturns that could negatively impact the biotechnology sector.
- The leveraged nature of the fund amplifies both gains and losses, making it a high-risk investment.
What Threats Does BIB Face?
- Negative news or market corrections in the biotechnology sector
- Increased competition from other leveraged ETFs
- Changes in regulations or tax laws
- Unexpected events that could disrupt the biotechnology industry
What Are BIB's Competitive Advantages?
- ProShares has a strong brand reputation and expertise in the leveraged ETF market.
- BIB offers a unique and specialized investment product that is not easily replicated.
- The fund benefits from the network effect of being part of the ProShares ETF family.
What Does BIB Do?
ProShares Ultra Nasdaq Biotechnology (BIB) is a financial instrument designed for investors seeking amplified daily exposure to the biotechnology sector. Launched by ProShares, a well-known provider of leveraged and inverse ETFs, BIB aims to deliver twice the daily performance of the Nasdaq Biotechnology Index. This index tracks the performance of a selection of NASDAQ-listed securities that are classified as biotechnology or pharmaceutical companies. BIB does not directly own the underlying stocks of the Nasdaq Biotechnology Index. Instead, it uses financial instruments like swaps, futures contracts, and other derivatives to achieve its 2x leveraged exposure. This approach allows BIB to magnify the gains (and losses) of the index on a daily basis. The fund is rebalanced daily to maintain its 2x leverage ratio, which can lead to compounding effects over longer periods. As an ETF, BIB offers investors the flexibility to trade it like a stock on exchanges. Its objective is to provide a tool for sophisticated investors who want to express a short-term view on the biotechnology sector. Due to its leveraged nature, BIB is not intended for long-term investment strategies and is more suitable for active traders who closely monitor market movements and understand the risks involved. The fund's performance is heavily dependent on the daily movements of the Nasdaq Biotechnology Index, making it a volatile investment option.
What Products and Services Does BIB Offer?
- ProShares Ultra Nasdaq Biotechnology seeks to provide daily investment results that correspond to two times the daily performance of the Nasdaq Biotechnology Index.
- The fund uses financial instruments such as swaps, futures contracts, and other derivatives to achieve its leveraged exposure.
- BIB is designed for investors who want to amplify their returns from the biotechnology sector.
- The fund is rebalanced daily to maintain its 2x leverage ratio.
- BIB offers investors the flexibility to trade it like a stock on exchanges.
- It provides a tool for sophisticated investors who want to express a short-term view on the biotechnology sector.
How Does BIB Make Money?
- BIB generates revenue through management fees charged to investors.
- The fund's profitability depends on its ability to accurately track the Nasdaq Biotechnology Index and provide the desired level of leverage.
- BIB's business model is based on providing a leveraged investment product to investors seeking to amplify their returns in the biotechnology sector.
What Industry Does BIB Operate In?
ProShares Ultra Nasdaq Biotechnology (BIB) operates within the asset management industry, specifically focusing on leveraged ETFs. The ETF market has experienced substantial growth in recent years, driven by increasing investor demand for diversified and cost-effective investment vehicles. Leveraged ETFs like BIB cater to investors seeking to amplify their returns, but they also come with higher risks. The biotechnology sector, which BIB tracks, is characterized by high growth potential, innovation, and regulatory scrutiny. The competitive landscape includes other leveraged and inverse ETFs, as well as traditional biotechnology mutual funds and ETFs. BIB's success depends on its ability to accurately track the Nasdaq Biotechnology Index and provide the desired level of leverage while managing risk effectively.
Who Are BIB's Key Customers?
- Active traders who seek short-term gains in the biotechnology sector.
- Sophisticated investors who understand the risks and benefits of leveraged ETFs.
- Financial advisors who use BIB as a tactical tool in their clients' portfolios.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 42 snapshots
| 2026-08-23 | 55 |
| 2026-08-31 | 55 |
| 2026-09-08 | 55 |
| 2026-09-16 | 55 |
| 2026-09-24 | 55 |
| 2026-10-04 | 55 |
| 2026-10-05 | 55 |
What changed?
The score has stayed at 55.
Over the same 30 days the stock moved -6.6%.
BIB Financials
Bull Case vs Bear Case
Bull Case
- Leveraged exposure to the biotechnology sector
- Flexibility to trade like a stock on exchanges
- Potential for amplified returns in a bullish market
- Part of the well-known ProShares ETF family
Bear Case
- High risk due to leveraged nature
- Daily rebalancing can lead to erosion of value over time
- Not suitable for long-term investment strategies
- Performance is heavily dependent on the movements of the Nasdaq Biotechnology Index
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
BIB Latest News
No recent news available for BIB.
BIB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BIB.
Price Targets
Wall Street price target analysis for BIB.
BIB MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BIB; grades run from A+ (80-100) to F (below 30).
ProShares - Ultra Nasdaq Biotechnology Financials Stock: Key Questions Answered
What are the main risks for BIB?
The primary risk for ProShares Ultra Nasdaq Biotechnology (BIB) is its leveraged nature, which amplifies both gains and losses. This means that even small negative movements in the Nasdaq Biotechnology Index can result in significant losses for BIB investors.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Leveraged ETFs are complex financial instruments and are not suitable for all investors. Investors should carefully consider their risk tolerance and investment objectives before investing in BIB.